Characterization of Visual Characteristics in Allergic Contact Dermatitis

Status Not yet recruiting

Clinical Trial Summary

Contact dermatitis (CD) is a common inflammatory skin disease, affecting approximately 15-20% of the general population in industrialized countries and ranking first among occupational diseases in many European countries. The patch test method aims at reproducing the eczematous lesions by applying occlusive patches containing the suspected allergens to the patient's healthy skin. It requires experienced medical staff to read the reaction. Newtones Technologies society has developed a new tool, the SkinCam®, able to capture high resolution cross and parallel images, allowing a quantification of color and relief of skin. This study aims to illustrate patch test results, describing skin appearance (color, roughness, shine), using photographs taken by the SkinCam®.

Clinical Trial Description

Contact dermatitis (CD) is a common inflammatory skin disease, affecting approximately 15-20% of the general population in industrialized countries and ranking first among occupational diseases in many European countries. Allergic contact dermatitis (ACD) typically presents as a severe skin inflammation with redness, edema, oozing and crusting. It is characterized by a delayed type IV hypersensitivity response mediated by allergen-specific T cells in sensitized individuals. Current diagnosis relies on clinical investigations by diagnostic patch testing with suspected allergenic chemicals. The patch test method aims at reproducing the eczematous lesions by applying occlusive patches containing the suspected allergens to the patient's healthy skin. It requires experienced medical staff to read the reaction. Newtones Technologies society has developed a new tool, the SkinCam®, able to capture high resolution cross and parallel images, allowing a quantification of color and relief of skin. This study aims to illustrate patch test results, describing skin appearance (color, roughness, shine), using photographs taken by the SkinCam®. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06351449
Study type	Observational
Source	Hospices Civils de Lyon
Contact	Audrey NOSBAUM, MD
Phone	418861572
Email	audrey.nosbaum@chu-lyon.fr
Status	Not yet recruiting
Phase
Start date	April 15, 2024
Completion date	April 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03945760` - Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects	Early Phase 1
Not yet recruiting	`NCT05498467` - The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis	Phase 3
Active, not recruiting	`NCT03680131` - Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis	Phase 2
Recruiting	`NCT05535738` - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation	Phase 2/Phase 3
Recruiting	`NCT06191627` - Patient Experience and Quality of Patch Testing on the Legs vs Back	N/A
Completed	`NCT00867607` - Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis	Phase 1/Phase 2
Recruiting	`NCT00445029` - Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation	N/A
Completed	`NCT04365140` - MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel
Recruiting	`NCT05991674` - A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques
Completed	`NCT00931242` - Study of Apremilast in Atopic or Contact Dermatitis	Phase 2
Completed	`NCT01798589` - Bioequivalence of Ethylenediamine Dihydrochloride Study	Phase 4
Completed	`NCT01546298` - Immune Reactions in Contact Dermatitis Affected Skin
Completed	`NCT05339750` - Allergy Skin Patch Artificial Intelligence (AI)	N/A
Recruiting	`NCT03935971` - The Effects of Dupilumab on Allergic Contact Dermatitis	Phase 4
Completed	`NCT01797562` - Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents	N/A
Not yet recruiting	`NCT05858723` - Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool	N/A
Completed	`NCT02534441` - Epidemiology and Co-Reactivity of Novel Surfactant Allergens	N/A
Not yet recruiting	`NCT01413477` - Nickel Desensitization Using Topical Therapy	N/A
Completed	`NCT00133341` - Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate	Phase 2
Completed	`NCT00132600` - Clinical Evaluation of Bacitracin	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Characterization of Visual Characteristics in Allergic Contact Dermatitis Using the Skincam® Tool — PatchCam

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms